Influence of preoperative chemotherapy for advanced thoracic oesophageal squamous cell carcinoma on perioperative complications

Background: The Japan Clinical Oncology Group (JCOG) 9907 trial has changed the standard of care for advanced thoracic oesophageal cancer in Japan from postoperative chemotherapy to preoperative chemotherapy. The impact of preoperative chemotherapy on the risk of developing postoperative complicatio...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of surgery Vol. 98; no. 12; pp. 1735 - 1741
Main Authors Hirao, M., Ando, N., Tsujinaka, T., Udagawa, H., Yano, M., Yamana, H., Nagai, K., Mizusawa, J., Nakamura, K.
Format Journal Article
LanguageEnglish
Published Chichester, UK John Wiley & Sons, Ltd 01.12.2011
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background: The Japan Clinical Oncology Group (JCOG) 9907 trial has changed the standard of care for advanced thoracic oesophageal cancer in Japan from postoperative chemotherapy to preoperative chemotherapy. The impact of preoperative chemotherapy on the risk of developing postoperative complications remains controversial. This article reports the safety analysis of JCOG9907, focusing on risk factors for postoperative complications. Methods: Patients with potentially resectable advanced thoracic oesophageal squamous cell carcinoma were randomized to either postoperative or preoperative chemotherapy followed by transthoracic oesophagectomy with D2–3 lymphadenectomy. Chemotherapy consisted of two cycles of cisplatin and 5‐fluorouracil. Clinical baseline data, intraoperative complications, postoperative complications and in‐hospital mortality, collected on the case report forms in a predetermined format, were analysed. Univariable and multivariable analyses were used to explore the risk of postoperative complications in relation to treatment group, age, sex, tumour depth, nodal metastasis, stage and location. Results: Of 330 patients randomized, 166 were assigned to receive postoperative chemotherapy and 164 preoperative chemotherapy; 162 and 154 patients respectively underwent surgery. The incidence of intraoperative complications, postoperative complications and in‐hospital mortality was similarly low in both groups. Multivariable analysis showed that age, sex and tumour location were independently associated with an increase in postoperative complications, but preoperative chemotherapy was not. Conclusion: Preoperative chemotherapy does not increase the risk of complications or hospital mortality after surgery for advanced thoracic oesophageal cancer. Registration number: NCT00190554 (http://www.clinicaltrials.gov). Copyright © 2011 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd. Does not increase post‐op complications
Bibliography:Presented to the 44th Annual Meeting of American Society of Clinical Oncology, Chicago, Illinois, USA, May 2008, and published in abstract form as J Clin Oncol 2008; 26(Suppl): Abstract 4510
istex:BB324592DF4EAE95A9F2629C503B60E07AD16254
ark:/67375/WNG-XJP1J2K6-X
ArticleID:BJS7683
2008
(Suppl): Abstract 4510
26
Presented to the 44th Annual Meeting of American Society of Clinical Oncology, Chicago, Illinois, USA, May 2008, and published in abstract form as
J Clin Oncol
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-News-2
ObjectType-Feature-3
content type line 23
ISSN:0007-1323
1365-2168
DOI:10.1002/bjs.7683